Department of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands.
Division of Pediatric Gastroenterology, Hepatology & Nutrition, Nationwide Children's Hospital, Columbus, OH, USA.
Neurogastroenterol Motil. 2018 Apr;30(4):e13294. doi: 10.1111/nmo.13294. Epub 2018 Jan 30.
Evidence for the efficacy of commonly used drugs in the treatment of childhood functional constipation (FC) is scarce, studies are often of low quality and study designs are heterogeneous. Thus, recommendations for the design of clinical trials in childhood FC are needed.
Members of the Rome Foundation and a member of the Pediatric Committee of the European Medicines Agency formed a committee to create recommendations for the design of clinical trials in children with FC.
This committee recommends conducting randomized, double-blind, placebo-controlled, parallel-group clinical trials to assess the efficacy of new drugs for the treatment of childhood FC. Pediatric study participants should be included based on fulfilling the Rome IV criteria for FC. A treatment free run-in period for baseline assessment is recommended. The trial duration should be at least 8 weeks. Treatment success is defined as no longer meeting the Rome IV criteria for FC. Stool consistency should be reported based on the Bristol Stool Scale. Endpoints of drug efficacy need to be tailored to the developmental age of the patient population.
在治疗儿童功能性便秘(FC)方面,常用药物的疗效证据稀缺,研究通常质量较低,且研究设计存在异质性。因此,需要为儿童 FC 的临床试验设计提出建议。
罗马基金会的成员和欧洲药品管理局儿科委员会的一名成员组成了一个委员会,旨在为儿童 FC 的临床试验设计制定建议。
本委员会建议开展随机、双盲、安慰剂对照、平行组临床试验,以评估治疗儿童 FC 的新药的疗效。应根据满足 FC 的罗马 IV 标准纳入儿科研究参与者。建议进行无治疗的洗脱期以进行基线评估。试验持续时间至少应为 8 周。治疗成功定义为不再符合 FC 的罗马 IV 标准。应根据布里斯托大便量表报告粪便稠度。药物疗效的终点需要根据患者人群的发育年龄进行调整。